Search results
Results from the WOW.Com Content Network
Adrenocorticotropic hormone (ACTH; also adrenocorticotropin, corticotropin) is a polypeptide tropic hormone produced by and secreted by the anterior pituitary gland. [1] It is also used as a medication and diagnostic agent .
The ACTH test (also called the cosyntropin, tetracosactide, or Synacthen test) is a medical test usually requested and interpreted by endocrinologists to assess the functioning of the adrenal glands' stress response by measuring the adrenal response to adrenocorticotropic hormone (ACTH; corticotropin) or another corticotropic agent such as tetracosactide (cosyntropin, tetracosactrin; Synacthen ...
Adrenocorticotropic hormone deficiency is a rare disorder characterized by secondary adrenal insufficiency with minimal or no cortisol production and normal pituitary hormone secretion apart from ACTH. [3] ACTH deficiency may be congenital or acquired, and its symptoms are clinically similar to those of glucocorticoid deficiency.
The primary control of cortisol is the pituitary gland peptide, ACTH, which probably controls cortisol by controlling the movement of calcium into the cortisol-secreting target cells. [87] ACTH is in turn controlled by the hypothalamic peptide corticotropin-releasing hormone (CRH), which is under nervous control.
Adrenocorticotropic hormone is used as a medication and as diagnostic agent in the ACTH stimulation test. [ 1 ] [ 2 ] : 316, 1165 [ 3 ] : 84, 271 The form that is purified from pig pituitary glands is known as corticotropin [ 1 ] [ 2 ] : 316 is a medication and naturally occurring polypeptide tropic hormone produced and secreted by the anterior ...
Inferior petrosal sinus sampling (or IPSS), is a diagnostic medical procedure used to determine whether excess adrenocorticotropic hormone (ACTH) is coming from the pituitary gland (usually a pituitary adenoma causing Cushing's disease) or from a source outside the pituitary (a rare tumor causing ectopic ACTH syndrome). The procedure is usually ...
The release of ACTH from the corticotropic cells is controlled by CRH, which is formed in the cell bodies of parvocellular neurosecretory cells within the paraventricular nucleus of the hypothalamus and passes to the corticotropes in the anterior pituitary via the hypophyseal portal system.
Atumelnant (INN Tooltip International Nonproprietary Name; developmental code name CRN04894) is an investigational new drug developed by Crinetics Pharmaceuticals for the treatment of adrenocorticotropic hormone (ACTH)-dependent endocrine disorders. [1]